Labcorp is buying more of OPKO Health's BioReference business in a deal worth up to $872 million, adding the FDA-approved 4Kscore blood test, clinical and women's health testing services, urology and corrections testing businesses, and more than 80 patient service centers. The company said its national diagnostics network could broaden physician access to 4Kscore, which helps gauge the likelihood of finding aggressive prostate cancer on biopsy, and expects the acquired assets to generate about $250 million in first-year revenue.

Why It Matters To Oncology

• 4Kscore is an FDA-approved blood test used to help assess the risk of aggressive prostate cancer before biopsy, making this acquisition directly relevant to prostate cancer detection and care pathways.

• Labcorp's scale could expand access to the test across its nationwide diagnostics footprint, potentially increasing uptake among community and specialist clinicians.

• For oncology drug discovery and development audiences, broader use of risk-stratification diagnostics may also shape patient identification, referral patterns, and real-world testing datasets in prostate cancer.

The Financials

• Labcorp will pay $722 million in cash at closing, with up to $150 million more tied to 4Kscore-related revenue, for a total potential value of $872 million.

• The deal follows Labcorp's prior acquisition of BioReference's oncology and related clinical testing operations for up to $225 million last year.

• Labcorp expects the newly acquired business to contribute about $250 million in revenue in the first year after closing.

What They're Saying

• Labcorp said its nationwide diagnostics network can make 4Kscore more widely available to physicians.

• OPKO chairman and CEO Phillip Frost said the transaction will let OPKO streamline operations and focus resources on its biopharmaceutical business.

• The structure underscores how diagnostic platform value is increasingly tied to both physical access points and proprietary test franchises.

What's Next

• Closing will determine when Labcorp can begin integrating the more than 80 service centers and the newly acquired testing businesses into its broader network.

• Clinicians should watch for any updates on 4Kscore availability, ordering workflows, payer coverage, and geographic reach after integration.

• For OPKO, the sale further narrows its focus toward biopharma as it exits additional diagnostic operations.